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Abstract
Background: Clinical trials designed to test the efficacy of retinoic acid (RA) as an adjuvant for the treatment of
solid cancers have been disappointing, primarily due to RA resistance. Estrogen receptor (ER)-negative breast cancer
cells are more resistant to RA than ER-positive cells. The expression and subcellular distribution of two RA-binding
proteins, FABP5 and CRABP2, has already been shown to play critical roles in breast cancer cell response to RA.
CRABP1, a third member of the RA-binding protein family, has not previously been investigated as a possible
mediator of RA action in breast cancer.
Methods: CRABP1 and CRABP2 expression in primary breast tumor tissues was analyzed using gene expression
and tissue microarrays. CRABP1 levels were manipulated using siRNAs and by transient overexpression. RA-induced
subcellular translocation of CRABPs was examined by immunofluorescence microscopy and immunoblotting.
RA-induced transactivation of RAR was analyzed using a RA response element (RARE)-driven luciferase reporter
system. Effects of CRABP1 expression and RA treatment on downstream gene expression were investigated by
semi-quantitative RT-PCR analysis.
Results: Compared to normal mammary tissues, CRABP1 expression is significantly down-regulated in ER+ breast
tumors, but maintained in triple-negative breast cancers. Elevated CRABP1 levels are associated with poor patient
prognosis, high Ki67 immunoreactivity and high tumor grade in breast cancer. The prognostic significance of
CRABP1 is attributed to its cytoplasmic localization. We demonstrate that CRABP1 expression attenuates RA-induced
cell growth arrest and inhibits RA signalling in breast cancer cells by sequestering RA in the cytoplasm. We also
show that CRABP1 affects the expression of genes involved in RA biosynthesis, trafficking and metabolism.
Conclusions: CRABP1 is an adverse factor for clinical outcome in triple-negative breast cancer and a potent inhibitor
of RA signalling in breast cancer cells. Our data indicate that CRABP1, in conjunction with previously identified CRABP2
and FABP5, plays a key role in breast cancer cell response to RA. We propose that these three RA-binding proteins
can serve as biomarkers for predicting triple-negative breast cancer response to RA, with elevated levels of either
cytoplasmic CRABP1 or FABP5 associated with RA resistance, and elevated levels of nuclear CRABP2 associated
with sensitivity to RA.
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Introduction
Current clinical management of breast cancer relies
on clinicopathological features as well as expression of
biological markers such as estrogen receptor (ER), pro-
gesterone receptor (PR) and epidermal growth factor
receptor 2 (HER2) [1, 2]. While tamoxifen has been
shown to be highly effective for the treatment of ER/PR-
positive breast cancers [3], there are no specific molecu-
lar targets for tumors that don’t express ER, PR or
HER2. These triple-negative tumors, which constitute
15–20 % of breast cancers [4], are more aggressive and
less responsive to standard treatment than the more
common ER/PR-positive breast cancers, and have a
poorer prognosis [5, 6].
RA and its derivatives, collectively called retinoids, in-
hibit growth and induce apoptosis in a variety of epithelial
cancer cells and hold great promise as chemotherapeutic
agents [7–9]. Retinoids inhibit mitogen signalling [10] and
induce downstream signalling pathways implicated in
growth arrest, apoptosis and differentiation of precancer-
ous and cancer cells [11–15]. However, with the exception
of acute promyelocytic leukemia (APL) [14, 16, 17],
clinical trials designed to test the efficacy of RA and its
derivatives in the treatment of cancer have produced
disappointing results, primarily because of RA-induced
side effects and development of RA resistance [18, 19].
RA exerts its physiological effects by binding and acti-
vating nuclear retinoic acid receptors RARα, β and γ.
RAR dimerizes with retinoid-X-receptor (RXR) and
binds to retinoic acid response elements (RARE) in the
promoters of target genes, regulating their transcription
and function [7–9]. As intracellular transporters, the
cellular RA binding proteins determine RA subcellular
distribution, fate and function [20–22]. Two RA binding
proteins, cellular retinoic acid binding protein 2 (CRABP2)
and fatty acid-binding protein 5 (FABP5), have been shown
to play opposing roles in mediating the RA cellular re-
sponse by targeting RA to distinct nuclear receptors;
i.e., delivery of RA to RARs by CRABP2 leads to inhib-
ition of cell proliferation, whereas delivery of RA to per-
oxisome proliferator activated receptor beta (PPARβ) by
FABP5 increases cell proliferation and causes RA resist-
ance [23, 24].
We previously reported that FABP5 is preferentially
expressed in ER- and triple-negative breast tumors [25],
subtypes that are prone to RA resistance [26–28]. Fur-
thermore, breast cancer cells with an elevated FABP5/
CRABP2 ratio show increased resistance to RA [23, 25].
However, the FABP5/CRABP2 ratio does not always pre-
dict breast cancer cell response to RA, and RA resist-
ance in the squamous cell carcinoma cell line COLO 16
cannot be overcome by either restoration of CRABP2
expression or an increased CRABP2/FABP5 ratio [29],
indicating that other factors are involved.
Studies designed to examine the importance of CRABP1
in the clinical outcomes of various cancers have produced
conflicting results [30–33]. Prior to this study, the expres-
sion and prognostic significance of CRABP1 in breast
cancer had not been investigated. In light of CRABP1’s
proposed role in attenuating RA activity by enhancing RA
metabolism, expression of CRABP1 in breast cancer could
have important implications for RA response. Here, we
report the expression, clinicopathological association and
function of CRABP1 in breast cancer. Our data indicate
that CRABP1 is an adverse prognostic factor and a potent
inhibitor of RA action in breast cancer which functions by
sequestering RA in the cytoplasm rather than by enhan-
cing RA metabolism. We propose that CRABP1 may serve
as a biomarker to predict RA response and a target to
optimize the efficacy of RA in breast cancer treatment.
Materials and methods
Chemicals, reagents and DNA constructs
All-trans retinoic acid was purchased from Sigma-Aldrich
(Oakville, ON, Canada) and dissolved in DMSO (Sigma-
Aldrich) at a concentration of 50 mM. Scrambled stealth
siRNAs and gene-specific siRNAs targeting different re-
gions of CRABP1 mRNA (nucleotides 381–405 and
484–508 of GenBank mRNA sequence NM_004378)
and CRABP2 mRNA (nucleotides 418–442 and 465–489
of GenBank mRNA sequence NM_001878) were pur-
chased from Life Technologies (Burlington, ON, Canada).
The Lipofectamine RNAiMAX reagent (Life Techno-
logies) was used for siRNA transfections. The pGL3-
RARE-luciferase plasmid DNA was purchased from
Addgene (Cambridge, MA, USA) and the luciferase assay
system from Promega (Madison, WI, USA). Polyethyleni-
mine (PEI) (Polysciences, Warrington, PA, USA) was used
for plasmid DNA transfections. For gain-of-function
studies, the entire open reading frame of CRABP1 was
PCR-amplified and cloned into pcDNA3 (Life Technologies).
Cell culture and siRNA transfection
ZR-75-1, MDA-MB-468, MDA-MB-435, BT-20, T47D,
BT-474, MDA-MB-231, BT-483, MCF-7, SK-Br-3, BT-
549 and Hs578T breast cancer cells were cultured in
Dulbecco’s modification of Eagle’s medium (DMEM)
supplemented with 10 % fetal calf serum, penicillin
(100 units/mL) and streptomycin (100 μg/mL). Cells
were grown at 37 °C in a humidified incubator with
5 % CO2. To knockdown CRABP1 and CRABP2, MCF-7
cells were transfected with 10 nM siRNA. The medium
was replaced with fresh medium 18 h after transfection
and the cells were cultured for an additional 48 h. Two
rounds of siRNA transfections were performed for each
experiment. Hs578T, BT-549 and SK-Br-3 cells were
transfected with 7 μg of empty (control) or pcDNA3 ex-
pression construct (CRABP1 or CRABP2) as previously
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described [34]. For cell proliferation assays, 10,000 siRNA-
transfected cells were seeded in each well of 12-well plates
and cultured overnight in DMEM containing 10 % FBS.
The medium was then replaced with FBS-supplemented
medium containing the indicated concentrations of RA
(or DMSO as a vehicle control). Five days later, cells were
counted using a Coulter Particle and Size Analyzer
(Coulter Corporation, Mississauga, Canada).
Immunofluorescence analysis
MCF-7 cells were cultured on coverslips for 24 h and
treated with 0.5 μM RA (dissolved in DMSO) or vehicle
(DMSO) in serum-free DMEM medium for 6 h. Cells
were then fixed in 1 % paraformaldehyde in PBS for
10 min and permeabilized in 0.5 % Triton X-100 for
5 min. Cells were immunostained with anti-CRABP1
or anti-CRABP2 antibodies, followed by Alexa 594-
conjugated donkey anti-mouse (for CRABP1) or Alexa
555-conjugated donkey anti-rabbit (for CRABP2) second-
ary antibodies (Life Technologies). Images were acquired
using a Zeiss LSM510 confocal microscope (Oberkochen,
Germany) with a 40 ×/1.3 oil immersion lens.
Patient population
A total of 176 treatment-naïve primary breast cancer sam-
ples and 10 normal breast tissue samples from reduction
mammoplasties were obtained from the Canadian Breast
Cancer Foundation Tumor Bank and used for gene ex-
pression microarray analysis as previously described [35].
Patient material and clinical information was collected
under Research Ethics Board Protocol ETH-02-86-17.
Tumor tissues were frozen and histologically analysed as
previously described [35].
Patients received standardized guideline-based chemo-
and hormone therapies: i.e., patients with ER-positive
tumors received hormone therapy, those with HER2-
positive tumors received trastuzumab, high-risk node-
negative disease was treated with anthracycline chemo-
therapy whereas anthracycline plus taxane chemotherapy
was used for the treatment of node-positive disease. The
176 patients selected for this study consisted of 88 patients
who experienced early relapse (<5 years after the initial
treatment) and 88 patients who had not relapsed. ER,
PR and HER2 status, stage and time of follow-up were
balanced between the two groups. The median follow-up
time for surviving patients was 4.5 years. The gene profil-
ing data used in this publication have been deposited in
NCBI [GEO Datasets: GSE22820].
RNA preparation, gene expression microarrays and RT-PCR
Total RNA was isolated from frozen human breast tumor
biopsies using the TRIzol reagent (Life Technologies) and
further purified with Qiagen RNeasy columns (Qiagen,
Mississauga, ON, Canada). The average percent of area
with tumor cells was 72.6 % and the average percent of
cells that were tumor cells was 93.4 %, for all tissues
analysed. Microarray hybridization was carried out as
previously described [35]. Reverse transcription-polymerase
chain reaction (RT-PCR) conditions were as previously
described [25, 34]. The number of cycles for each pri-
mer pair was optimized for quantitative amplification
within the exponential PCR product growth phase. PCR
primers are listed in Additional file 1: Table S1. PCR
amplification of human β-actin mRNA served as posi-
tive control as previously described [25]. For real-time
quantitative RT-PCR (qRT-PCR), we used the following
TaqMan FAM-labeled Gene Expression Assay primers:
human CRABP1 (Hs00171635_m1), human CRABP2
(Hs00275636_m1) and human GAPDH (Hs03929097).
cDNA samples were analysed in triplicate, with each
cDNA undergoing 40 cycles of amplification in 96-well
reaction plates (10 μL volume) using TaqMan Gene Ex-
pression Master Mix (Applied Biosystems 7900HT Real-
Time PCR System).
Generation of tissue microarrays and immunohistochemical
(IHC) staining
Tissue microarrays (TMA) (TMArrayer, Pathology
Devices) were generated using all available formalin-
fixed paraffin-embedded breast tumor tissues repre-
senting 120 patients out of the 176-patient cohort used
for gene expression analysis. The TMA slides contained
triplicate core tissue samples (0.6 mm in diameter) from
each tumor. TMAs were immunostained with anti-
CRABP1 monoclonal antibody (Sigma-Aldrich; 1:200
dilution) and anti-CRABP2 polyclonal antibody (Protein
Tech Group; 1:200 dilution). The signal was detected using
EnVision + anti-mouse (CRABP1) or anti-rabbit (CRABP2)
secondary systems (DakoCytomation, Carpinteria, CA).
Tissues were counterstained with hematoxylin. Cytoplas-
mic and nuclear staining were scored separately based on
the average staining signal intensity throughout the tumor
tissue on a scale of 0 (negative), 1 (weak), 2 (moderate) and
3 (strong). Of the 120 tumor samples tested, 105 and 106
had sufficient tissue for analysis of CRABP1 and CRABP2
immunoreactivity, respectively.
Western blotting
Cytoplasmic and nuclear extracts were prepared according
to Dignam et al. [36], and whole cell lysates were prepared
using Dignam buffer A plus 0.5 % SDS. Cytoplasmic pro-
tein (20 μg), nuclear protein (20 μg) and whole cell protein
(40 μg) were separated by SDS-polyacrylamide gel electro-
phoresis and transferred to nitrocellulose membranes
by electroblotting. Membranes were immunostained with
primary antibodies in 5 % bovine serum albumin (in 1X
Tris-buffered saline) at 4 °C overnight. The signal was
detected with horseradish peroxidase-conjugated secondary
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antibodies using the ECL Western Blotting Detection
Reagent (GE Healthcare Life Sciences, USA). The fol-
lowing primary antibodies were used for western blot
analysis: anti-CRABP1 (1:1,000), anti-CRABP2 (1:1,000),
β −actin (Sigma-Aldrich; 1:100,000), α-tubulin (DSHB;
1:10,000) and Lamin A/C (ThermoFisher; 1:1,000).
Luciferase reporter assay
After siRNA depletion of CRABP1 or CRABP2, MCF-7
cells were seeded in 12-well culture plates at 20,000
cells/well and transfected with the luciferase reporter
construct (0.5 μg/well) under the control of a retinoic
acid response element (RARE) (pGL3-RARE-luc, Addgene).
Alternatively, CRABP1-negative cell lines (BT-549, SK-Br-3,
Hs578T) were seeded in 12-well plates, incubated at 37 °C
for 24 h and then co-transfected with the CRABP1 ex-
pression construct (0.8 μg/well) and pGL3-RARE-Luc
(0.5 μg/well) diluted in 250 μL of serum-free medium
containing 5 μL PEI. pcDNA3 empty vector served as
the negative control for these experiments. Forty-eight h
after transfection, cells were treated with RA (in DMSO)
at final concentrations of 0, 0.1 and 0.5 μM for 6 h keeping
the overall volume of DMSO constant in each well. Cells
were then harvested and whole cell lysates prepared using
the luciferase cell culture lysis reagent (CCLR, Promega).
Luciferase activity was measured with the Luciferase Assay
System (Promega) and quantitated using a FLUOstar
OPTIMA microplate reader (BMG Labtech) following the
manufacturer’s instructions. Triplicate wells were analyzed
for each treatment.
Statistical analysis
Statistical analysis was performed using MedCalc Statis-
tical Software version 12.7.2 (MedCalc Software, Ostend,
Belgium) as previously described [25]. Briefly, gene pro-
filing data for CRABP1 and CRABP2 were classified as
“low” or “high” by receiver operating characteristic (ROC)
curve analysis. Student t-test or chi-square test was used
to examine the significance of associations between
CRABP mRNA levels or immunoreactivity and clinical
outcome parameters. Two-way ANOVA was used to
test the significance of the effects of siRNA knockdown
and RA treatment on cell proliferation. The prognostic
significance of CRABP1 and CRABP2 was analyzed by
logrank test on Kaplan-Meier survival curves using both
gene profiling and TMA immunoassay data.
Results
CRABP1 is expressed in ER- and triple-negative breast
tumors and is associated with poor clinical outcomes
Based on our gene profiling data, CRABP1 is markedly
down-regulated in ER-positive breast tumors in keeping
with reports indicating that CRABP1 is silenced in cancer
cells [30, 31, 33, 37]. However, CRABP1 expression is
maintained in ER/PR-negative breast tumors compared
to normal mammary tissues (Fig. 1a and Table 1). In
contrast, CRABP2 mRNA levels are significantly up-
regulated in ER-positive tumors compared to normal
and triple-negative tumor tissues (Fig. 1a and Table 1).
Neither CRABP1 nor CRABP2 levels showed statistically
significant difference between HER2-overexpressing tu-
mors and other tissue types. These data indicate that there
is an inverse relationship between CRABP1 and CRABP2
expression in triple-negative compared to ER/PR-positive
tumors
Next, we analysed CRABP expression in a sampling of
ten cDNA samples from patient breast tumor tissues
using real-time qRT-PCR analysis. CRABP1 mRNA was
detected at elevated levels (~2 to 11-fold relative to the
first tumor sample which was set at 1) in 4 out of 6
triple-negative tumors; however, none of the four non-
triple negative tumors showed relative levels larger than
1 (Fig. 1b). In contrast, CRABP2 mRNA was found at
higher levels in non-triple-negative tumors (~3 to 9-fold
relative to MT633) compared to triple-negative tumors
(with 1 out of 6 tumors showing relative levels higher
than 1) (Fig. 1c).
We also screened a panel of 11 breast cancer cell lines
for CRABP1 and CRABP2 expression. CRABP1 was de-
tected at elevated levels (4.5–6.8-fold relative to ZR-75-1
which was set at 1) in two non-triple-negative breast
cancer cell lines (MCF-7 and BT-483), with none of the
five triple-negative cell lines having levels higher than 1
(Fig. 1d). These results suggest that CRABP1 expression
is not retained in triple-negative breast cancer cells
under in vitro growth conditions, perhaps as a conse-
quence of changes in the microenvironment [38]. A
similar phenomenon has been reported for other pro-
teins and cancers, including loss of glial fibrillary acidic
protein and brain fatty acid-binding protein in malignant
glioma cell lines compared to tumor tissue [39–41].
CRABP2 was expressed at elevated levels (2–28-fold
relative to ZR-75-1) in all six non-triple-negative breast
cancer cell lines, while only two out of five triple-
negative cell lines had relative CRABP2 levels higher
than 1 (Fig. 1e).
We then examined the association of CRABP mRNA
levels in primary breast tumors with major clinicopatho-
logical parameters (Table 1). High CRABP1 mRNA levels
correlated with positive nodal status (p = 0.021), high
nuclear grade (p < 0.0001), mitotic grade (p < 0.0001) and
overall histological tumor grade (p < 0.0001) (Table 1).
Such correlations were not observed with CRABP2
mRNA levels. Kaplan-Meier survival analysis further
showed that high levels of CRABP1 mRNA were signifi-
cantly (p = 0.0083) associated with lower patient survival
probability (Fig. 1f), whereas high levels of CRABP2
mRNA were significantly associated with better prognosis
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Fig. 1 Distinct mRNA expression patterns and prognostic associations of CRABP1 and CRABP2 in breast tumors. a Comparison of CRABP1 and
CRABP2 mRNA levels (based on normalized gene microarray signal intensity) in normal mammary tissues (n = 10) and human breast cancer
subtypes (n = 176). b, c CRABP1 (b) and CRABP2 (c) mRNA levels in tumor tissues sampled from the 176 breast cancer patient cohort. The MT and
GT numbers refer to individual patients. RNA levels were measured by real-time quantitative RT-PCR with GAPDH serving as the internal control.
Expression levels from triplicate reactions are shown relative to MT633. d, e CRABP1 (d) and CRABP2 (e) mRNA levels in a panel of 11 breast cancer
cell lines. RNA levels were analysed by real-time quantitative RT-PCR and shown as fold change relative to ZR-75-1. f Kaplan-Meier overall patient
survival curves generated based on low and high CRABP1 mRNA levels determined by ROC analysis. g Kaplan-Meier overall patient survival curves
generated based on low and high CRABP2 mRNA levels. n, denotes sample size; *, p < 0.05; **, p < 0.01
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Table 1 Clinicopathological associations of CRABP1 and CRABP2 in human breast cancers
Factor Classification cDNA microarray Tissue microarray
n Geometric
mean
p Cytoplasmic immunoreactivity Nuclear immunoreactivity
Negative Positive p Negative Positive p
CRABP1 ER Negative 64 4.16 <0.0001 20 21 0.0058 28 13 0.0583
Positive 112 0.67 49 15 54 10
PR Negative 82 2.80 <0.0001 27 25 0.0040 37 15 0.1031
Positive 94 0.67 42 11 45 8
Her2 Negative 146 1.39 0.2038 53 31 0.3119 63 21 0.1512
Positive 30 0.94 16 5 19 2
Triple negative No 120 0.72 <0.0001 52 17 0.0051 59 10 0.0142
Yes 56 4.63 17 19 23 13
Death No 119 1.13 0.1641 49 18 0.0532 53 9 0.8078
Yes 57 1.74 20 18 29 14
Recurrence No 88 1.21 0.6020 36 10 0.0225 39 7 0.1615
Yes 88 1.40 33 26 43 16
Nodal status pN0 69 0.81 0.021 26 14 1.0000 31 9 1.0000
pN1-3 107 1.21 42 22 51 14
Cancer stage I 45 1.63 0.1635 21 3 0.0133 22 2 0.0919
II–III 131 1.21 48 33 60 21
Nuclear grade Low 44 0.34 <0.0001 20 4 0.0050 24 0 0.0015
High 132 2.04 49 32 58 23
Mitotic grade Low 78 0.48 <0.0001 36 7 0.0016 41 2 0.0003
High 98 2.91 33 29 41 21
Arch grade Low 29 0.76 0.0929 10 0 0.0145 10 0 0.1129
High 147 1.45 59 36 72 23
Overall grade Low 56 0.41 <0.0001 25 5 0.0221 30 0 0.0002
High 120 2.24 44 31 52 23
Cytoplasmic immunoreactivity Nuclear immunoreactivity
0 1 2 3 p 0 1 2 3 p
CRABP2 ER Negative 64 0.63 <0.0001 7 18 13 3 0.0613 5 11 13 12 0.0010
Positive 112 1.37 3 29 19 14 0 6 25 34
PR Negative 82 0.73 0.0002 8 23 17 4 0.0371 5 12 19 16 0.0070
Positive 94 1.40 2 24 15 13 0 5 19 30
Her2 Negative 146 0.95 0.0369 9 39 24 13 0.6762 4 15 30 36 0.8405
Positive 30 1.53 1 8 8 4 1 2 8 10
Triple negative No 120 1.32 p < 0.0001 4 30 22 14 0.1545 1 6 28 35 0.0019
Yes 56 0.61 6 17 10 3 4 11 10 11
Death No 119 1.12 0.2089 4 34 21 9 0.1819 1 12 28 27 0.0843
Yes 57 0.87 6 13 11 8 4 5 10 19
Recurrence No 88 1.02 0.8998 3 26 13 5 0.1837 1 11 18 17 0.1567
Yes 88 1.04 7 21 19 12 4 6 20 29
Nodal status pN0 69 1.78 0.0819 4 20 14 3 0.2813 2 8 19 12 0.1308
pN1-3 107 1.07 6 27 18 14 3 9 19 34
Cancer stage I 45 0.81 0.0895 3 13 7 2 0.5660 2 4 11 8 0.5062
II–III 131 1.12 7 34 25 15 3 13 27 38
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(p = 0.0028; Fig. 1g). Again, these results suggest opposing
roles for CRABP1 and CRABP2 in breast cancer clinical
outcomes.
Subcellular localization of CRABP1 determines prognostic
significance
CRABPs serve as intracellular chaperones for RA and
modulate its nuclear availability and biological activity
[42, 43]. The subcellular localization of CRABPs is there-
fore a critical determinant of their function. To investigate
whether there is any association between the subcellular
distribution of CRABP1 and 2 and clinical outcomes, we
conducted immunohistochemical analysis of a TMA
containing primary tumor samples from 120 breast can-
cer patients. We first validated the specificity of our
anti-CRABP1 and anti-CRABP2 antibodies by western
blot analysis of whole cell lysates prepared from MDA-MB-
435 cells (negative for both CRABP1 and 2) transfected
with CRABP1 or CRABP2. No cross-immunoreactivity was
observed for these two antibodies (Fig. 2a).
We found that 34.3 % and 21.9 % of the scored tumors
showed positive cytoplasmic and nuclear CRABP1 im-
munoreactivity, respectively (Fig. 2b and Table 1). TMA
tissues with different CRABP1 and CRABP2 cytoplasmic
Table 1 Clinicopathological associations of CRABP1 and CRABP2 in human breast cancers (Continued)
Nuclear grade Low 44 1.12 0.5981 1 12 7 4 0.7638 1 2 11 10 0.5616
High 132 1.05 9 35 25 13 4 15 27 36
Mitotic grade Low 78 1.11 0.4743 2 19 13 10 0.2547 0 4 17 23 0.0618
High 98 0.98 8 28 19 7 5 13 21 23
Arch grade Low 29 1.20 0.4399 1 6 3 1 0.8747 0 1 3 7 0.5014
High 147 1.00 9 41 29 16 5 16 35 39
Overall grade Low 56 1.04 0.9369 1 15 10 5 0.5695 0 3 14 14 0.2344
High 120 1.03 9 32 22 12 5 14 24 32
Fig. 2 Immunoreactivity and subcellular distribution of CRABP1 and CRABP2 in a human primary breast tumor TMA. a Western blot of CRABP1 and
CRABP2 in MDA-MB-435 cells transfected with a CRABP1 or CRABP2 expression construct, respectively. b Frequency of breast tumors with different
subcellular immunoreactivity scores for CRABP1 and CRABP2: 0, negative; 1, weak; 2, intermediate; 3, strong. c Selected tissue sections from a human
breast cancer TMA immunostained with anti-CRABP1 and anti-CRABP2 antibodies. Nuclear (Nuc) and cytoplasmic (Cyt) scores are indicated
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Fig. 3 (See legend on next page.)
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and nuclear immunostaining intensities are shown in
Fig. 2c. Elevated levels of CRABP1 in the cytoplasm, but
not in the nucleus, was associated with negative ER (p =
0.0058) and PR status (p = 0.004). Both cytoplasmic and
nuclear CRABP1 immunoreactivities were positively cor-
related with triple-negative status and high histological
tumor grade (Table 1).
In contrast to CRABP1, the great majority of breast
tumor tissues scored positive for CRABP2, with 90.7 %
and 95.4 % of the scored samples showing cytoplasmic
and nuclear CRABP2 immunoreactivity, respectively
(Fig. 2b and Table 1). Close to half (43.5 %) of the tu-
mors showed strong nuclear CRABP2 immunoreactivity
(score = 3), with a strong cytoplasmic CRABP2 signal
observed in 16.7 % of tumors (Fig. 2b–c). Nuclear
CRABP2 protein levels were positively correlated with
positive ER (p = 0.001), PR (p = 0.007) and overall non-
triple negative status (p = 0.0019). A correlation was also
observed between high cytoplasmic CRABP2 levels and
positive PR status (p = 0.0371, Table 1). No correlations
with other clinicopathological parameters were observed
for both cytoplasmic and nuclear CRABP2 immunoreac-
tivity (Table 1).
We then correlated subcellular levels of CRABPs with
patient survival probabilities. We found that patients
with tumors that were positive for cytoplasmic, but not
nuclear, CRABP1 had a significantly lower patient sur-
vival probability (p = 0.0091) (Fig. 3a–b). In contrast, nu-
clear, but not cytoplasmic, CRABP2 immunoreactivity
was positively associated with patient survival probability
(p = 0.0127) (Fig. 3c–d). Thus, our TMA analysis shows
that: (i) the clinicopathological associations of CRABP1
and 2 at the protein level are in good agreement with
that of the gene profiling data, (ii) CRABP1 is more fre-
quently found in the cytoplasm whereas CRABP2 is
more abundant in the nucleus of primary breast tumors,
and (iii) clinical outcome and prognostic implications
can be attributed to cytoplasmic CRABP1 and nuclear
CRABP2, suggesting distinct subcellular functions.
CRABP1 correlates with tumor cell proliferation and is a
potent inhibitor of RA signalling
To further understand the opposing roles of CRABP1 and
CRABP2 in breast cancer progression, we immunostained
our breast cancer TMA with Ki67, a cell proliferation
marker (Additional file 1: Figure S1), and examined its
correlation with CRABP protein levels. We found that
both cytoplasmic (p = 0.024) and nuclear (p = 0.008)
CRABP1 levels were positively correlated with Ki67 im-
munoreactivity (Fig. 3e). In contrast, neither cytoplas-
mic nor nuclear CRABP2 levels correlated with Ki67
protein levels (Fig. 3g). As expected, the mRNA levels of
Ki67 also showed significant positive correlation with
that of CRABP1, but not CRABP2 mRNA, based on gene
profiling analysis (Fig. 3f, h). These results suggest that
CRABP1 may affect breast cancer progression by enhan-
cing tumor cell proliferation through modulation of RA
signalling. The lack of correlation between CRABP2 and
Ki67 suggests that the effect of CRABP2 on patient
survival may be mediated through differentiation and
apoptosis rather than proliferation, as previously re-
ported for APL [17, 44].
CRABP1 and CRABP2 may play distinct roles in RA/
RAR-mediated transcriptional activity [42, 45]. To inves-
tigate the role of CRABP1 in RA action, we used siRNAs
to deplete the RA-responsive MCF-7 cells of either
CRABP1 or CRABP2 (Fig. 4a–b). A small but statisti-
cally significant increase in growth inhibition was ob-
served when CRABP1-depleted cells were treated with
RA, with control cells showing 81 and 74 % relative
growth at 0.1 μM and 0.5 μM RA, respectively, and
CRABP1-depleted cells showing 65 and 66 % relative
growth at 0.1 μM and 0.5 μM RA, respectively (Fig. 4c).
A stronger growth inhibition effect was observed upon
treatment of CRABP1-depleted cells with RA in the ab-
sence of serum (Additional file 1: Figure S2). In contrast
to CRABP1, knockdown of CRABP2 had little effect on
RA-mediated cell growth inhibition (91 % at 0.1 μM and
88 % at 0.5 μM) (Fig. 4c).
The growth inhibitory effect of RA is believed to be
mediated through activation of RARs [23, 24, 45]. We
therefore examined the effect of CRABP1 and CRABP2
on RA-induced RAR activation using the luciferase re-
porter system. We used two different siRNAs to deplete
each of the two CRABP genes in MCF-7 cells. CRABP-
depleted MCF-7 cells were then transfected with a
RA-responsive RARE-luciferase vector and treated with
RA. An RA dose-dependent induction in luciferase activity
(See figure on previous page.)
Fig. 3 Associations of subcellular CRABP1 and CRABP2 levels with breast cancer patient survival and Ki67 immunoreactivity. CRABP1, CRABP2 and
Ki67 protein levels were determined by immunohistochemical analysis of a TMA containing triplicate cores for each tumor from a 120 primary
breast tumor cohort. a-b Association of cytoplasmic and nuclear CRABP1 levels with patient survival. c-d Association of cytoplasmic and nuclear
CRABP2 levels with patient survival. e Positive correlation of cytoplasmic and nuclear CRABP1 protein levels with Ki67 immunoreactivity. f Positive
correlation of CRABP1 and Ki67 mRNA levels based on gene microarray analysis. g No significant correlation was observed between subcellular
CRABP2 levels and Ki67 immunoreactivity. h No correlation was evident between CRABP2 and Ki67 mRNA levels. HR, hazard ratio; p, statistical
significance level; r, correlation coefficient. Scores: 0, negative; 1, weak; 2, intermediate; 3, strong. As the size of samples expressed CRABP1 is small
in our TMAs, tumor samples were classified into “positive” and “negative” groups for survival analysis
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Fig. 4 (See legend on next page.)
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(indicative of RAR activation) was observed for both con-
trol and siRNA transfected cells (Fig. 4d–e). However,
CRABP1 depletion resulted in a ~2-fold increase in RAR
activation in the presence of RA compared to control cells,
whereas depletion of CRABP2 resulted in decreased RAR/
RA-mediated transcriptional activity (Fig. 4d–e). These re-
sults suggest that in contrast to CRABP2 which plays a
positive role in RAR activation, CRABP1 may serve as an
inhibitor of RA signalling in breast cancer cells.
We then co-transfected two triple-negative breast can-
cer cell lines (Hs-578 T and BT-549) and one ER-
negative/HER2 overexpressing cell line (SK-Br-3) with a
CRABP1 expression construct and the RARE-luciferase
reporter vector. CRABP1 expression in transfected cells
was verified by western blotting (Fig. 4f ). Endogenous
CRABP1 was not detected in any of these three cell
lines. Luciferase activity was induced by RA in all three
cell lines in a dose-dependent manner in cells trans-
fected with empty vector (Fig. 4g–i). A significant reduc-
tion in RA-induced RAR activation was observed in all
three cell lines upon transfection with the CRABP1 ex-
pression construct. Specifically, SK-Br-3 and Hs578T
cells showed reduced RAR-activation in both 0.1 μM
and 0.5 μM RA-treated cells upon CRABP1 expression
(Fig. 4h–i). Reduced luciferase activity was only observed
at the highest concentration of RA tested in BT-549 cells
(Fig. 4g).
Next, we analysed CRABP1 and CRABP2 subcellular
localization in response to RA in MCF-7 cells. Both pro-
teins were primarily found in the cytoplasm in the ab-
sence of RA (Fig. 5a). In contrast to CRABP2 which
translocated to the nucleus upon RA treatment, there
was no change in CRABP1 subcellular localization upon
RA treatment (Fig. 5a). These results are consistent with
a general role for CRABP1 in sequestering RA in the
cytoplasm, rendering it unavailable for RAR activation.
CRABP1 attenuates RA signalling through modulation of
the expression of RA responsive genes
To further explore the mechanism involved in CRABP1/
RA-mediated effects in breast cancer cells, we examined
the expression of critical genes implicated in RA synthe-
sis, trafficking, metabolism and action upon CRABP1
manipulation and RA treatment. MCF-7 cells were
transfected with scrambled or CRABP1 siRNAs and
treated with increasing amounts of RA. Levels of
CRABP2, a facilitator of RA signalling to the nucleus
[46], were upregulated upon CRABP1 depletion in the
absence of RA (Fig. 5b). Upon RA treatment, CRABP2
levels were induced in control cells in a dose-dependent
manner but not in CRABP1-depleted cells. The tran-
scription factor AP-2α (TFAP2A), a RA-inducible gene
with tumor-suppressing activity [47, 48], was upregu-
lated by CRABP1 depletion and RA treatment at a dose
up to 5 nM. The expression of the RA metabolizing en-
zyme CYP26A1 was induced at high concentrations of
RA (500 nM RA) in both control and CRABP1-depleted
cells, with enhanced up-regulation observed in the latter.
The observation that CYP26A1 levels are up-regulated
to a higher degree in CRABP1-depleted compared to
control cells argues against the idea that CRABP1 pro-
motes RA metabolism [49–51]. The expression of alde-
hyde hydrogenase ALDH1B1 gene, which is involved in
RA biosynthesis and associated with cancer cell stem-
ness [52], was induced by RA in the control cells but
not in the CRABP1-depleted cells. Interestingly, the two
cellular retinol-binding protein genes (RBP1 and RBP7),
encoding proteins that facilitate retinol uptake, storage
and/or metabolism [53–56], exhibited opposite expres-
sion patterns upon CRABP1 knockdown and RA treat-
ment, with RBP1 being induced by RA in both control
cells and CRABP1-depleted cells, and RBP7 being down-
regulated by CRABP1 depletion and suppressed by RA
in a dose-dependent manner. These results (summarized
in Fig. 5c) indicate that CRABP1 has an inhibitory effect
on RA action through modulation of a spectrum of
genes involved in various aspects of the RA network in-
cluding RA biosynthesis, metabolism and intracellular
trafficking.
Next, we examined the effect of CRABP1 expression
on the nuclear translocation of CRABP2, which is an im-
portant indication of RA signalling to the nucleus [57].
(See figure on previous page.)
Fig. 4 CRABP1 and CRABP2 differentially modulate RA-induced growth inhibition and RAR transcriptional activity. a, b Western blot analysis of
MCF-7 cells transfected with CRABP1 or CRABP2 siRNAs using antibodies against CRABP1 or CRABP2. c Relative growth rate of MCF-7 cells treated
with the indicated concentrations of RA after transfection with non-specific (control) and specific siRNAs targeting CRABP1 or CRABP2. Signifi-
cance of difference was tested using two-way ANOVA. d RAR transactivation (measured by luciferase activity) of CRABP1a-depleted or CRABP2a-
depleted MCF-7 cells transfected with a luciferase reporter construct under the control of a RARE. Cells were treated with DMSO (vehicle control)
or RA for 6 h before harvest. Luciferase activity (a measure of RAR activation) is shown as fold change relative to cells that were cultured in the
absence of RA. e The luciferase assay was repeated with a second set of siRNAs targeting CRABP1 and CRABP2 (CRABP1b, CRABP2b). f Western
blots showing ectopic expression of CRABP1 in three human breast cancer cell lines. g, h, i The effects of ectopic expression of CRABP1 on RAR
transactivation (measured by luciferase activity) were examined in BT-549 (g), SK-Br-3 (h) and Hs578T (i) cells co-transfected with a CRABP1 cDNA
construct and a RARE-luciferase reporter construct. Cells were treated with RA for 6 h at the indicated concentrations. Luciferase activity (a meas-
ure of RAR activation) was adjusted based on protein concentrations of individual lysates and shown as fold change relative to control cells trans-
fected with empty vector and cultured in the absence of RA. KD, denotes knockdown; *, p < 0.05; **, p < 0.01
Liu et al. Molecular Cancer  (2015) 14:129 Page 11 of 16
SK-Br-3 cells were transfected with a CRABP1 expres-
sion construct and treated with RA. We observed higher
levels of cytoplasmic and nuclear CRABP2 upon RA
treatment in control cells (Fig. 5d). Furthermore, a
marked decrease in nuclear CRABP2 levels was observed
in CRABP1-overexpressing cells upon RA treatment.
Taken together, these results suggest that CRABP1 acts
as an inhibitor of RA action by restricting RA access
to the nucleus through down-regulation of nuclear
CRABP2 levels.
Our results suggest that CRABP1, in addition to the
previously identified FABP5 and CRABP2, is a key factor
regulating breast cancer cell response to RA. To explore
the possibility that expression levels of these three RA
binding proteins might be useful predictors of primary
breast tumor sensitivity to RA, we analyzed their relative
mRNA levels in our 176 breast cancer patient cohort
based on gene microarray analysis. CRABP1 and FABP5,
encoding RA binding proteins associated with RA resist-
ance, were 5.2- and 1-fold higher, respectively, in ER-
negative breast tumors compared to ER-positive tumors.
On the other hand, levels of CRABP2, a positive modula-
tor of RA signalling and activity, were 1.2-fold higher in
ER-positive compared to ER-negative tumors (Fig. 6a).
These results suggest that CRABP1 in particular may
play an important role in the RA resistance observed in
ER-negative tumors.
Discussion
Cellular response to RA is believed to depend on two
different classes of nuclear receptors, RARs and PPARs
[23, 24]. RAR activation by RA results in cell growth in-
hibition whereas PPARδ/β activation stimulates cell pro-
liferation. These two RA signaling pathways are in turn
modulated by two intracellular RA binding proteins:
CRABP2 which channels RA to the nucleus to target
RAR, and FABP5 which delivers RA to the nucleus
thereby activating PPARδ/β [23, 24]. We previously
showed that FABP5 is preferentially expressed in ER-
and triple-negative breast cancers, molecular subtypes
believed to be resistant to RA treatment [25]. High levels
of FABP5, as well as a low ratio of CRABP2 to FABP5,
Fig. 5 a Subcellular localization of CRABP1 and CRABP2 in MCF-7 cells treated with RA. Cells were cultured in medium with serum for 24 h and then
treated with 0.5 μM RA in serum-free medium for 6 h. An equivalent amount of DMSO was added to control cells. Cells were immunostained with anti-
CRABP1 (red, upper panel) or anti-CRABP2 (red, lower panel) antibodies as described in Materials and Methods. DAP1 (blue) staining was used to visualize
the nucleus. b Expression of RA-responsive genes in MCF-7. MCF-7 cells underwent two rounds of transfection with scrambled or CRABP1 siRNAs. Cells
were treated with increasing concentrations of RA [lanes 1 to 6 (0, 5 × 10−5, 5 × 10−4, 5 × 10−3, 5 × 10−2, 5 × 10−1 μM RA)]. RNA was purified from each
culture and semi-quantitative RT-PCR was carried out using gene-specific primers (Additional file 1: Table S1). c Summary of the effect of CRABP1 and RA
on downstream genes and pathways. dWestern blots showing the subcellular distribution of CRABP2 in SK-Br-3 cells upon CRABP1 overexpression and
RA treatment. Densitometric analysis was used to quantitate CRABP2 signal intensity in the cytoplasm and nucleus relative to the cytoplasmic marker
(β-tubulin) and nuclear marker (lamin A/C), respectively. Changes in band intensities are shown as fold change in relation to lane 1 (for cytoplasmic
CRABP2) and lane 5 (for nuclear CRABP2)
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are associated with poor prognosis. In this study, we
identify a third RA-binding protein, CRABP1, as an in-
hibitor of RA action and an adverse factor for clinical
outcome in breast cancer. Like FABP5, CRABP1 is pref-
erentially expressed in ER- and triple-negative breast
cancer. We propose a model whereby CRABP1 can
compensate or synergize with FABP5 to compete with
CRABP2 for RA, by sequestering RA in the cytoplasm,
thereby reducing RA access to RAR (Fig. 6b).
The role of CRABP1 in carcinogenesis and tumor
progression is poorly understood and contradictory. For
example, CRABP1 is down-regulated in some human
cancers and cell lines [31–33], with DNA methylation
proposed to contribute to CRABP1 silencing [33, 58–60].
DNA methylation-mediated silencing of CRABP1 has
been observed in a subset of breast carcinoma tissues
[60]. CRABP1 has been proposed to be a tumor sup-
pressor in esophageal squamous cell carcinoma, with
reduced CRABP1 levels associated with increased cell
growth and distant lymph node metastasis [33]. Re-
duced levels of CRABP1 are also associated with poorer
prognosis in serous (n = 40) and clear cell ovarian
adenocarcinoma (n = 59) [31]. On the other hand, high
levels of CRABP1 have been linked to lymph node me-
tastasis and poor differentiation/high grade in pancre-
atic neuroendocrine tumors [30].
In agreement with a pro-carcinogenic role for CRABP1,
we found an association between CRABP1 expression and
worse clinical outcomes in breast cancer using both gene
profiling and TMA analysis. Similar to a previous report
indicating that CRABP1 is differentially expressed in dif-
ferent subtypes of pituitary adenomas [37], we found that
CRABP1 is downregulated in ER+ breast tumors, but
expressed in ER- and triple-negative tumors. These results
suggest that downregulation of CRABP1 expression in
cancer cells may be modulated by specific signaling
pathways in different cancer subtypes (e.g. estrogen
signalling), and that its role in tumor progression may
differ between cancer types. It is noteworthy that estro-
gen signaling has been linked to the regulation of DNA
methylation, perhaps explaining to some extent the
reduced expression of CRABP1 observed in ER+ com-
pared to ER- breast cancers [61].
CRABP1 has the highest RA binding affinity of all RA
binding proteins [42]. It is generally believed that CRABP1
represses cellular response to RA by sequestering RA and/
or promoting RA catabolism, reducing its availability in
the nucleus for activation of RARs [51, 62–64]. Several
studies have demonstrated that CRABP1 promotes RA
metabolism [49–51]. However, the fact that RA metabo-
lites can activate RAR in vitro [65], combined with the ob-
servation that a positive relationship exists between RA
metabolism and cell growth inhibition in several cancer
cell lines [66], suggest that CRABP1-mediated RA metab-
olism may not account for RA resistance. In light of our
observations that: (i) cytoplasmic CRABP1 in breast tu-
mors is an adverse factor in clinical outcomes and (ii)
CRABP1 accumulates in the cytoplasm of cells treated
with RA, we propose that the primary role of CRABP1 in
breast cancer is to sequester RA in the cytoplasm, thereby
preventing RAR activation in the nucleus (Fig. 6b). The
up-regulation of the RA-metabolizing gene CYP26A1 ob-
served upon CRABP1 depletion at high RA concentration
further suggests a negative association between CRABP1
and RA metabolism.
Fig. 6 Schematic representation of the effects of different RA
binding proteins on modulation of RA action in breast cancer.
a Relative mRNA levels of FABP5, CRABP1 and CRABP2 in ER-negative
(n = 64) and ER-positive (n = 112) primary breast cancer tissue samples.
The mRNA levels for each gene were determined based on the
normalized signal intensity of the gene microarray data and are
shown relative to CRABP2 (set as 1) in the case of ER-negative tumors
and FABP5 (set as 1) in the case of ER-positive tumors. These data
provide insight as to the possible underlying cause of RA resistance
in ER-negative tumors. b A schematic model illustrating the distinct
roles of CRABP1, CRABP2 and FABP5 in modulating cellular response to
RA in breast cancer cells. FABP5 channels RA to PPARδ/β, a nuclear
receptor which promotes cell proliferation. CRABP1 sequesters RA
in the cytoplasm. CRABP2 delivers RA to RAR, leading to cell growth
inhibition. The balance between FABP5/CRABP1 and CRABP2 expression
levels determines the cellular response to RA (cell growth promotion
or inhibition)
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Over five hundred genes are known to be regulated by
RA, including CRABP2 which has a functional RARE in its
promoter region [67, 68]. CRABP2 serves as a positive
regulator of RA signalling in breast cancer cells [23, 24, 42]
and its expression can be induced by RA in various cell
types [67–69]. In this study, we found that CRABP1 and
CRABP2 have inverse expression patterns in breast tumors
and play an opposing role in the mediation of RA action in
breast cancer cells. We further report that CRABP1 nega-
tively regulates CRABP2 expression. While increased
CRABP2 expression has been observed in AB1 embryonic
stem cells with homozygous deletion of CRABP1 [70], this
is the first report demonstrating that CRABP1 has an in-
hibitory effect on CRABP2 expression in cancer cells. Intri-
guingly, CRABP1 not only inversely regulates CRABP2
expression, but also affects nuclear translocation of
CRABP2 in breast cancer cells. We postulate that CRABP1
plays a key role in attenuating RA activity in breast cancer
cells, with high levels of CRABP1 reducing availability of
RA in the nucleus. In turn, RA sequestration to the cyto-
plasm represses RA-mediated nuclear translocation of
CRABP2 and induction of CRABP2 expression.
In addition to CRABP2, our data indicate that CRABP1
modulates the expression of various genes implicated in
RA biosynthesis, metabolism and action. With the ex-
ception of RBP7, all these genes have previously been
shown to be RA-regulated [68]. We observed that the
genes encoding CYP26A1 (catalyzes RA metabolism) and
ALDH1B1 (catalyzes RA biosynthesis) are up-regulated
and down-regulated, respectively, in the presence of RA
upon CRABP1 depletion. We speculate that this is due to a
feedback process as CRABP1 depletion may increase levels
of free RA (especially when cells are exposed to high doses
of RA), in turn resulting in accelerated RA metabolism and
reduced RA synthesis. Therefore, CRABP1 may play a role
in regulating cellular levels of free RA. RBP1 and RBP7 are
retinol binding proteins which facilitate retinol storage and/
or retinol-RA conversion [53–56]. The different expression
patterns observed for these two genes in control and
CRABP1-depleted MCF-7 cells suggests opposite roles. We
propose that RBP1 (upregulated by RA but not affected by
CRABP1) may be involved in retinol storage whereas RBP7
(down-regulated by RA and CRABP1 depletion) may be in-
volved in retinol metabolism producing RA.
TFAP2A is a RA-inducible gene whose expression in-
creased upon CRABP1 knockdown in MCF-7 cells.
TFAP2A encodes AP-2α, recently shown to be essential
for RA action [71], has previously been reported to
stimulate CRABP2 expression in mammary epithelial
cells and breast cancer cells [72]. AP-2α significantly en-
hances RA-induced RAR activation in breast cancer cells
(our unpublished data). These combined data suggest
the presence of a CRABP1-AP-2α-CRABP2 axis which
modulates RA action in breast cancer cells.
In summary, we show that CRABP1 expression is
maintained in ER- and triple-negative breast tumors,
and that elevated levels of CRABP1 is a significant indi-
cator of high tumor grade, Ki67 immunoreactivity, and
poor prognosis. Our data indicate that cytoplasmic
CRABP1, like FABP5, is a potent inhibitor of RA signal-
ling. Elevated levels of CRABP1 may lead to RA resist-
ance in breast cancer cells through sequestration of RA
in the cytoplasm thereby preventing RA-mediated in-
duction of RAR. We further demonstrate that CRABP1
attenuates RA activity by modulating the expression of
important RA-regulated genes implicated in cellular RA
availability, traffic and action. Thus, both CRABP1 and
FABP5 represent potential therapeutic targets to over-
come RA resistance in breast cancer. The discovery that
there are at least three proteins involved in RA transport
in breast cancer cells (CRABP1, CRABP2 and FABP5
[23–25]), helps to address the molecular mechanism
governing RA resistance in ER-negative or triple-negative
breast cancer, and provides molecular tools to predict and
eventually overcome RA resistance in breast cancer pre-
vention and therapy.
Additional file
Additional file 1: Table S1. Nucleotide sequences of PCR primers.
Figure S1. Sample images of Ki67 immunohistochemical staining of a
human breast cancer TMA. The percentages shown are the averages of
the percent Ki67 positive cells in three TMA cores of the same tumor.
Tumor ID numbers are indicated at the bottom. Figure S2. Effect of
CRABP1 expression on RA-induced cell growth inhibition in MCF-7
cells. Cells were transfected with siRNA targeting CRABP1 (CRABP1 kd)
or scrambled siRNA (control). Transfected cells were then seeded in a
96-well plate, cultured for 24 h and then treated with RA in serum-free
medium at the indicated concentrations for two days. Cell proliferation
was analyzed using the MTS cell proliferation assay system (Promega)
following the manufacturer’s protocol. Significance of difference was
analyzed by two-way ANOVA. *denotes p < 0.05 and **p < 0.01.
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